Novo Nordisk's future under the microscope  

Financial newspaper Børsen publishes an analysis of Novo Nordisk's future prospects in the diabetes market

Daily financial newspaper Børsen has conducted a fresh analysis of Novo Nordisk's future in the diabetes market, which is published today. Børsen sees two options for the Danish company; either to strengthen their grip on the fast growing market for the medical treatment of Type 2 diabetes (non insulin dependent diabetes) or to merge with an international pharmaceutical giant. Business observers predict that a decision on Novo Nordisk's future is likely to be made within the next 5 years.


Diabetes is growing on an epidemic scale worldwide as Western lifestyle habits – characterised by fatty food, sedentary occupations and too little exercise – spread around the globe. Forecasts predict that in five years time the diabetes treatment market will be worth more than DKK 150 billion (USD 20 billion) worldwide, and in 10 years the figure is likely to be close to DKK 300 billion (USD 40 billion).

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×